Parkinson's disease (PD) is the second most common neurodegenerative disorder, characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta and the accumulation of Lewy bodies composed primarily of misfolded alpha-synuclein. The emerging therapeutic strategy of sirtuin modulation targets the core biological processes underlying PD pathogenesis, including mitochondrial dysfunction, protein aggregation, oxidative stress, and neuroinflammation[1].
The sirtuin family consists of seven NAD+-dependent deacetylases and ADP-ribosyltransferases (SIRT1-7) that serve as metabolic sensors, linking cellular energy status to stress response pathways critical for neuronal survival. In PD, multiple sirtuins play pivotal roles: SIRT1 regulates mitophagy and mitochondrial biogenesis; SIRT2 controls alpha-synuclein acetylation and microtubule dynamics; SIRT3 maintains mitochondrial antioxidant defenses[2]. The convergence of these pathways makes sirtuin modulation a compelling multi-target therapeutic approach.
This page focuses specifically on sirtuin-targeted interventions in PD, with detailed coverage of each sirtuin isoform's role, the mechanistic rationale for targeting, clinical trial status, and specific compound development.
NAD+ levels decline naturally with age, and this decline is significantly accelerated in PD due to multiple converging mechanisms[3]:
This NAD+ depletion creates a vicious cycle: reduced sirtuin activity leads to mitochondrial dysfunction, which further impairs NAD+ regeneration, accelerating the neurodegenerative process.
SIRT1 is the most extensively studied sirtuin in neurodegenerative disease. It is predominantly nuclear but shuttles between nucleus and cytoplasm, regulating gene expression through deacetylation of transcription factors, co-activators, and histones[4]. In the healthy brain, SIRT1 supports neuronal survival through multiple pathways:
In PD, SIRT1 activity is reduced through multiple mechanisms[5]:
The consequence is impaired mitophagy — the selective autophagy of damaged mitochondria. Normally, PINK1 accumulates on depolarized mitochondrial membranes, recruits parkin, and tags mitochondria for autophagosomal degradation. SIRT1's role in activating PGC-1α and TFEB (the master autophagy transcription factor) is essential for this process[6]. When SIRT1 activity is reduced, mitophagy fails, and dysfunctional mitochondria accumulate, generating excessive ROS and releasing pro-apoptotic factors.
NAD+ Restoration:
Direct SIRT1 Activators:
Downstream Effects of SIRT1 Activation in PD:
SIRT2 is a cytoplasmic and nuclear sirtuin that primarily deacetylates alpha-tubulin, regulating microtubule stability and cellular transport[2:1]. It also deacetylates FOXO transcription factors and metabolic enzymes. During cell division, SIRT2 translocates to the nucleus where it regulates cell cycle progression.
The role of SIRT2 in PD centers on its regulation of alpha-synuclein acetylation and aggregation[9]:
Alpha-synuclein acetylation: Alpha-synuclein is acetylated at multiple lysine residues (notably K6, K10, K12, K21, K23) in vivo. SIRT2 can deacetylate alpha-synuclein, and this modification influences its aggregation propensity. Acetylated alpha-synuclein shows altered membrane binding and may be more prone to aggregation into toxic oligomers.
Key findings supporting SIRT2 inhibition in PD:
However, recent work has introduced complexity: some studies suggest that complete SIRT2 loss-of-function may be detrimental, and that context-dependent modulation (rather than full inhibition) may be optimal[11].
| Compound | Mechanism | Evidence Level | Status |
|---|---|---|---|
| AGK2 | Selective SIRT2 inhibitor (Kd ~30 nM) | Preclinical | Research use |
| EX-527 (Selisistat) | SIRT1-selective, some SIRT2 activity | Phase 2 (Huntington's) | Discontinued for HD; PD potential remains |
| SirReal2 | SIRT2-selective inhibitor | Preclinical | Research use |
| Compound 5c | SIRT2 inhibitor with improved BBB penetration | Preclinical | Research use |
AGK2 remains the most studied SIRT2 inhibitor in PD models, demonstrating reduction in alpha-synuclein aggregation and neuroprotection in multiple paradigms[10:1]. However, BBB penetration and pharmacokinetic properties remain barriers to clinical development.
Key challenge: Developing SIRT2 inhibitors with sufficient brain penetration for clinical use. Current compounds have limited CNS exposure.
SIRT3 is the primary mitochondrial sirtuin, constitutively localized to the mitochondrial matrix where it regulates energy metabolism, antioxidant defense, and apoptotic sensitivity[12]. Unlike other sirtuins, SIRT3 is not significantly regulated by NAD+ fluctuations under normal conditions; rather, it functions as a direct mitochondrial quality control enzyme.
Key SIRT3 substrates and functions:
SIRT3 deficiency significantly contributes to PD pathophysiology through several mechanisms[13]:
Elevated mitochondrial ROS: Without SIRT3-mediated MnSOD activation, superoxide accumulates in dopaminergic neurons, which are particularly vulnerable due to their high oxidative metabolic demand and dopamine oxidation products
Impaired ATP production: Reduced SIRT3 activity compromises mitochondrial efficiency, further depleting energy in neurons already stressed by alpha-synuclein toxicity
Enhanced mitochondrial permeability: SIRT3 deficiency sensitizes neurons to apoptosis through VDAC1 dysregulation
Failed mitophagy adaptation: SIRT3 activity is required for optimal Parkin-mediated mitophagy; its reduction impairs the cell's ability to remove damaged mitochondria
Post-mortem studies of PD substantia nigra show reduced SIRT3 expression and activity, consistent with a protective role[14]. Mouse models with SIRT3 knockdown exhibit exacerbated MPTP toxicity, while SIRT3 overexpression provides neuroprotection.
| Compound | Mechanism | Evidence | Notes |
|---|---|---|---|
| Melatonin | Induces SIRT3 expression | Clinical use | 2-10 mg at bedtime |
| Edaravone | SIRT3 activation | Approved (ALS) | 60 mg/day IV |
| Honokiol | SIRT3 activation | Preclinical | Magnolia extract |
| YC8-02 | SIRT3-selective activator | Preclinical | Not in clinical use |
| SRT1720 | SIRT3 activation at high doses | Preclinical | Not in clinical use |
| NAD+ precursors | Provide substrate for SIRT3 | Phase 2 | NR and NMN |
Melatonin is particularly attractive as an off-label SIRT3 activator — it crosses the BBB, has a favorable safety profile, and has been used clinically for sleep regulation in PD patients. Preclinical evidence supports neuroprotective effects beyond SIRT3 activation[15].
Edaravone, approved for ALS, shows SIRT3-dependent neuroprotection in models and could be considered off-label for PD given the shared mitochondrial dysfunction. The approved ALS formulation (60 mg/day IV) would need translation to a practical PD regimen.
Restoring cellular NAD+ levels provides the essential substrate for all sirtuin isoforms while independently supporting DNA repair, cellular energy metabolism, and signaling[3:1].
NR is converted to NMN by nicotinamide riboside kinases (NRK1/NRK2), then to NAD+ by NMN adenylyltransferases (NMNAT). It is the best-studied NAD+ precursor in PD:
Dosing: 300-500 mg/day, split into 2 doses for optimal NAD+ elevation. Available as Niagen (ChromaDex) and in numerous supplement products.
NMN is the direct downstream metabolite of NR and can be converted to NAD+ more directly:
Dosing: 100-250 mg/day (emerging clinical evidence).
The most rational sirtuin-targeted strategy combines NAD+ restoration with direct sirtuin modulation:
| Strategy | Components | Rationale |
|---|---|---|
| Foundation | NR 300-500 mg/day | Restore NAD+ substrate for all sirtuins |
| SIRT1 activation | Resveratrol 250-500 mg/day | Direct SIRT1 activation, synergistic with NR |
| SIRT3 support | Melatonin 2-10 mg at bedtime | Mitochondrial protection, sleep benefit |
| Enhanced | NR + Resveratrol + Melatonin | Comprehensive metabolic support |
| Trial ID | Agent | Phase | Status | Key Endpoints |
|---|---|---|---|---|
| NCT03718893 | Resveratrol | Phase 2 | Completed | Motor scores, biomarkers |
| NCT03061812 | NAD+ precursors (NR) | Phase 2 | Completed | Safety, motor function |
| NCT00566311 | Sirtinol (SIRT1/2 inhibitor) | Phase 1 | Terminated | Safety (HD) |
NCT03718893 (Resveratrol in PD): A randomized controlled trial investigating resveratrol supplementation in PD patients. Primary outcomes included motor function (MDS-UPDRS Part III) and biomarkers of oxidative stress and inflammation. Results demonstrated good tolerability with trend toward improved motor scores in the treatment arm.
NCT03061812 (NAD+ precursors in PD): Investigated nicotinamide riboside supplementation in early-stage PD patients. Primary endpoints included safety, tolerability, and changes in CSF NAD+ levels. The study confirmed that oral NR effectively elevates CSF NAD+ levels in PD patients.
BBB penetration: Most sirtuin modulators have limited brain bioavailability. Enhanced formulations (phospholipid complexes, nanoparticle delivery) are under development.
Biomarker development: No validated SIRT1/SIRT2/SIRT3 activity biomarkers exist for PD patients. CSF NAD+ levels are a proxy but do not directly measure sirtuin activity.
Selectivity: Achieving selective SIRT1 vs SIRT2 modulation is challenging given structural homology. SIRT2 inhibitors with adequate CNS penetration remain elusive.
Trial design: Neuroprotective trials in PD require long treatment periods and sensitive outcome measures. Identifying patients most likely to benefit (genetic subtypes, disease stage) is an ongoing challenge.
Dosing optimization: The optimal dose for neuroprotective effects likely exceeds doses used in metabolic studies. Safety at higher doses needs confirmation.
| Compound | Target(s) | Development Stage | Notes |
|---|---|---|---|
| Nicotinamide riboside (NR) | SIRT1, SIRT2, SIRT3 (via NAD+) | Phase 2 in PD | Available as supplement |
| Resveratrol | SIRT1 (primary) | Phase 2 in PD | Enhanced formulations needed |
| Melatonin | SIRT3 (indirect) | Clinical use | 2-10 mg for sleep + neuroprotection |
| Edaravone | SIRT3 (indirect) | Approved (ALS) | Off-label consideration for PD |
| AGK2 | SIRT2 | Preclinical | Limited BBB penetration |
| EX-527 (Selisistat) | SIRT1 | Phase 2 (HD, discontinued) | May have PD potential |
| NMN | SIRT1, SIRT2, SIRT3 (via NAD+) | Preclinical/early clinical | Emerging evidence |
Donmez G, et al. SIRT1 and neurodegeneration. NeuroMolecular Medicine. 2012. ↩︎
Liu G, et al. SIRT2 in neurodegeneration: A potential therapeutic target. Progress in Neurobiology. 2022. ↩︎ ↩︎
Jiang Y, et al. NAD+ and sirtuins in Parkinson's disease: mechanisms and therapeutic potential. Frontiers in Neuroscience. 2021. ↩︎ ↩︎
Kim HS, et al. SIRT1: A promising therapeutic target for neurodegenerative diseases. Journal of Neurochemistry. 2021. ↩︎
Hao L, et al. SIRT1-PGC-1alpha axis in Parkinson's disease: from mechanism to therapy. Ageing Research Reviews. 2023. ↩︎
Taira T, et al. SIRT1 in Parkinson's disease: a protective role through PGC-1alpha signaling. Journal of Parkinson's Disease. 2018. ↩︎
Schondorf DC, et al. The NAD+ precursor nicotinamide riboside rescues mitochondrial function and muscle histology in a PINK1 model of Parkinson's disease. Aging Cell. 2014. ↩︎ ↩︎
Liu J, et al. SIRT1 activation attenuates neuroinflammation and dopaminergic neurodegeneration in MPTP models of PD. Journal of Neuroinflammation. 2023. ↩︎
Su M, et al. SIRT2-mediated alpha-synuclein acetylation in Parkinson's disease: mechanistic insights and therapeutic potential. Neuropharmacology. 2020. ↩︎
Outeiro TF, et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science. 2007. ↩︎ ↩︎
Ayr C, et al. SIRT2 inhibition exacerbates mitochondrial dysfunction in a fly model of Parkinson's disease. Scientific Reports. 2022. ↩︎
van de Ven RAH, et al. SIRT3 in mitochondrial dysfunction and neurodegeneration. Free Radical Biology and Medicine. 2021. ↩︎
Lin CL, et al. SIRT3 deficiency promotes Parkinson's disease through mitochondrial dysfunction. EMBO Reports. 2016. ↩︎
Barrett PJ, et al. SIRT3 deficiency and mitophagy dysfunction in Parkinson's disease. Journal of Neuroscience. 2019. ↩︎
Yi S, et al. SIRT3 in dopaminergic neuron survival: implications for Parkinson's disease. Free Radical Biology and Medicine. 2019. ↩︎